Literature DB >> 10908020

Early predictors of mortality in pneumococcal bacteraemia.

I Balakrishnan1, P Crook, R Morris, S H Gillespie.   

Abstract

OBJECTIVES: Pneumococcal bacteraemia carries a mortality of about 20%. Approximately 50% of deaths from pneumococcal bacteraemia occur within the first 48 h of admission. In order to influence outcome, critically ill patients should be identified at the time of presentation. This study enables the clinician to rapidly make an evidence-based assessment of a patient's prognosis, allowing the identification of patients who should be placed in a high-risk category at an early stage, when appropriate management is most likely to be effective.
METHODS: Data were collected from the medical record of history, physical examination, radiological examination and laboratory investigations done on initial presentation using a standardized proforma. The data were first examined by Pearson's Chi-squared test, with Yates' correction if needed. Variables found to be significantly associated with case fatality ( P < 0.05) by these methods were examined by stepwise logistic regression analysis in order to identify those factors which were independent predictors of case fatality.
RESULTS: The overall case fatality was 21%. Older age, apyrexia, tachypnoea, bilateral consolidation, hypoalbuminaemia, elevated aminotransferases, renal impairment, acidosis and leucopaenia were significantly associated with higher case fatality. Older age, acidosis and elevated serum alanine aminotransferase (ALT) were independent predictors of case fatality. Fifty-five percent of isolates belonged to serotypes 4, 6B, 9V, 14, 19F and 23F, to which good antibody levels have been documented in both young and elderly patients post-vaccination. Serotype 14 was most common, and was significantly associated with higher case fatality. Colder weather was associated with a higher incidence of both infection and case fatality. The case fatality amongst patients receiving ITU management was 44%. Less than 50% of patients who died received ITU management.
CONCLUSIONS: Despite the increased availability of new antibiotics and vaccines, the mortality of patients with pneumococcal bacteraemia remains unchanged. The parameters above allow early identification of patients with a higher case fatality; these patients may benefit from being placed in a "high-risk" category early on in their management. Vaccination of the elderly may reduce the incidence and/or mortality from pneumococcal bacteraemia. Further studies are required to understand the reasons for referral for intensive therapy in acute pneumococcal bacteraemia and whether ITU management affects outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908020     DOI: 10.1053/jinf.2000.0653

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  10 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Permissive hypercapnia--role in protective lung ventilatory strategies.

Authors:  John G Laffey; Donall O'Croinin; Paul McLoughlin; Brian P Kavanagh
Journal:  Intensive Care Med       Date:  2004-01-14       Impact factor: 17.440

3.  Critical roles of ASC inflammasomes in caspase-1 activation and host innate resistance to Streptococcus pneumoniae infection.

Authors:  Rendong Fang; Kohsuke Tsuchiya; Ikuo Kawamura; Yanna Shen; Hideki Hara; Shunsuke Sakai; Takeshi Yamamoto; Teresa Fernandes-Alnemri; Ruili Yang; Eduardo Hernandez-Cuellar; Sita R Dewamitta; Yanting Xu; Huixin Qu; Emad S Alnemri; Masao Mitsuyama
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

4.  Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Ravinder Kaur; Naveen Surendran; Martina Ochs; Michael E Pichichero
Journal:  Infect Immun       Date:  2014-09-22       Impact factor: 3.441

5.  NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populations.

Authors:  S J Chapman; C C Khor; F O Vannberg; A Rautanen; S Segal; C E Moore; R J O Davies; N P Day; N Peshu; D W Crook; J A Berkley; T N Williams; J A Scott; A V S Hill
Journal:  Genes Immun       Date:  2009-10-01       Impact factor: 2.676

Review 6.  Hypoalbuminemia as Surrogate and Culprit of Infections.

Authors:  Christian J Wiedermann
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

7.  Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study.

Authors:  Leah J Ricketson; Alberto Nettel-Aguirre; Otto G Vanderkooi; Kevin B Laupland; James D Kellner
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

8.  Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4.

Authors:  Yufeng Su; Dagen Li; Yan Xing; Hong Wang; Jian Wang; Jun Yuan; Xiaofang Wang; Fang Cui; Yibing Yin; Xuemei Zhang
Journal:  Front Immunol       Date:  2017-06-12       Impact factor: 7.561

9.  Increased susceptibility for superinfection with Streptococcus pneumoniae during influenza virus infection is not caused by TLR7-mediated lymphopenia.

Authors:  Sabine Stegemann; Sofia Dahlberg; Andrea Kröger; Marcus Gereke; Dunja Bruder; Birgitta Henriques-Normark; Matthias Gunzer
Journal:  PLoS One       Date:  2009-03-17       Impact factor: 3.240

10.  Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection.

Authors:  Damon P Eisen; Melinda M Dean; Marja A Boermeester; Katy J Fidler; Anthony C Gordon; Gitte Kronborg; Jürgen F J Kun; Yu Lung Lau; Antonis Payeras; Helgi Valdimarsson; Stephen J Brett; W K Eddie Ip; Joan Mila; Mark J Peters; Saedis Saevarsdottir; J W Oliver van Till; Charles J Hinds; Emma S McBryde
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.